Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ningetinib in advanced and metastatic renal cell cancer
NCT03876925Phase 2Terminated
- Sponsor
- Sunshine Lake Pharma
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ningetinib in renal cell carcinoma (RCC), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate up to 24 months. Started Jun 2018; status: terminated.
02
Drugs
ningetinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03876925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876925.